

POLICY NAME	Acute CGRP Antagonist Therapies	POLICY #	2769P
--------------------	---------------------------------	-----------------	--------------

Criteria

Coverage Criteria for Nurtec/Ubrelvy

- ☐ **1.1** Diagnosis of moderate to severe migraine, with or without aura, according to the International Classification of Headache Disorders
- ☐ **1.2** Age 18 years or older
- ☐ **1.3** For patients with 4 or more migraine days per month, documentation that the member is on 1 supported migraine preventative therapy such as amitriptyline, nortriptyline, venlafaxine, duloxetine, topiramate, divalproex, metoprolol, Botox, etc. with claims history to support member compliance with filling at least a 90 day supply within a 120 day time frame
- ☐ **1.4** One of the following:
 - Trial of at least two generic triptan therapies (almotriptan, rizatriptan, frovatriptan, others) with little to no relief of moderate/severe migraine symptoms, OR
 - Contraindication to triptan therapy defined as one of the following: ☐ History of stroke or transient ischemic attack ☐ History of hemiplegic or basilar migraine ☐ Peripheral vascular disease; ischemic bowel disease ☐ Uncontrolled hypertension ☐ Recent use (within 2 weeks) of MAO inhibitors ☐ Recent use (within 24 hours) of treatment with another 5-HT₁ agonist, or an ergot-containing or ergot-type medication (e.g., methysergide, dihydroergotamine) ☐ Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) ☐ Coronary artery vasospasm, including Prinzmetal variant angina, or other significant underlying cardiovascular disease ☐ Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders ☐ Patients with risk factors for coronary artery disease (CAD) such as hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male > 40 years of age) in whom adequate cardiac evaluation has not ruled out CAD

Coverage Criteria for Zavzpret

- ☐ **2.1** Diagnosis of moderate to severe migraine, with or without aura, according to the International Criteria References Classification of Headache Disorders
- ☐ **2.2** Age 18 years or older
- ☐ **2.3** For patients with 4 or more migraine days per month; must be stable on at least 1 supported migraine preventative therapy such as amitriptyline, nortriptyline, venlafaxine, duloxetine, topiramate, divalproex, metoprolol, Botox, etc.
- ☐

2.4 Trial of at least one oral triptan AND sumatriptan nasal spray with little to no relief of migraine symptoms

- Accepted contraindications to triptan therapy are described above
- Bypass oral triptan trial if documentation supports nausea/vomiting with migraines

Exclusion Criteria – Any of the following prevents coverage

- ☐ 4.1 Abortive CGRP antagonists will not be approved if being used in combination with another calcitonin gene- related peptide (CGRP) inhibitor such as Aimovig, Emgality, or Vyepti.
-
- ☐ 4.2 Abortive CGRP antagonists will not be approved if being used in combination with Reyvow (lasmiditan)